增加尼格罗斯特里亚特回路中的多巴胺合成增加了相位多巴胺释放,并改变了背向带连接:对精神分裂症的影响
Sunil Srivastav1, Xiaoying Cui1,2, Roger Bitencourt Varela1
1Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Schizophrenia (Heidelberg, Germany)
|October 5, 2023
概括
精神分裂症的研究表明,脊椎条纹体 (DS) 中多巴胺 (DA) 的增加. 我们的老鼠模型 (EDiPs) 显示,这增强了DA释放,改变了大脑连接,为疾病进展提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 神经生物学 神经生物学 神经生物学
背景情况:
- 精神分裂症与多巴胺 (DA) 合成和释放在背条体 (DS) 中的升高有关.
- 这种超多巴胺状态与精神病症状和疾病进展相关.
研究的目的:
- 研究增强的DA合成能力如何影响DA释放生理学和DS连接.
- 为了表征EDiPs (增强多巴胺在prodromal精神分裂症) 鼠标模型.
主要方法:
- 利用病毒载体在整个发育过程中诱导大鼠的DS中增加DA合成.
- 采用快速扫描循环电压测量来测量DA释放动态.
- 使用免疫组织化学的量化突触架构,专注于DA释放部位和谷氨酸突触.
主要成果:
- 在EDiPs的老鼠中,在DS中DA分相释放量增加,而强力DA水平保持不变.
- 在DS的TH +轴突中观察到 Bassoon 前突触标记物的水平升高.
- 在EDiP的DS中,注意到囊泡性谷氨酸转运体1 (VGluT1) 突触的密度增加,这表明皮质输入发生了变化.
结论:
- 该EDiPs模型复制了精神分裂症前兆的关键神经化学特征.
- 增强的DA合成能力导致改变了DS中的DA释放和突触连接.
- 研究结果提供了关于精神分裂症中高多巴胺激素的长期功能后果的见解.
更多相关视频
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
705
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
705
Biological Causes of Schizophrenia
65
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
65
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Parkinson's Disease: Treatment
287
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
287
Excitatory and Inhibitory Effects of Neurotransmitters
10.0K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.0K


